

January 27, 2026



# **NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026**

FORT MYERS, Fla.--(BUSINESS WIRE)-- **NeoGenomics, Inc. (NASDAQ: NEO)**, a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its fourth quarter and full year 2025 financial results prior to the open of the U.S. financial markets on Tuesday, February 17, 2026. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights.

The live webcast may be accessed by visiting the Investor Relations section of our website at [ir.neogenomics.com](http://ir.neogenomics.com) or by clicking [here](#). The webcast will be archived and available for replay shortly after the conclusion of the call.

To access the live call via telephone, dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior to the call. The participant access code is 825997.

## **About NeoGenomics, Inc.**

NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20260127745368/en/>

## **Investor Contact**

Kendra Webster

[InvestorRelations@neogenomics.com](mailto:InvestorRelations@neogenomics.com)

## **Media Contact**

Andrea Sampson

[asampson@sampsonprgroup.com](mailto:asampson@sampsonprgroup.com)

Source: NeoGenomics, Inc.